Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 244 participants, all of whom received the treatment being studied — a medicine called risankizumab. The trial was measuring how people with psoriasis responded to this treatment, looking mainly at how a doctor rated the appearance of their skin, and also at how participants themselves felt about their symptoms and daily life. Of the 244 people who started, 205 completed the study, and 39 did not complete it. The primary outcome used a skin scoring tool called the sPGA (Static Physician Global Assessment), where a doctor rates psoriasis on a scale from 0 (completely clear) to 4 (severe). The main result being tracked was how many participants reached a score of 0 or 1 — meaning their skin was rated as clear or almost clear. The reported data shows that 140 participants achieved this result at the primary time point. The reported data also shows a number of secondary measurements: at a later time point, 152 participants were recorded as reaching a sPGA score of 0 or 1, and 66 participants reached a score of 0 (completely clear skin), compared with 50 participants at the earlier time point. Additionally, 98 participants reported a score of 0 or 1 on a quality-of-life questionnaire (where lower scores indicate less impact on daily life), and 51 participants reported a score of 0 on a symptom scale measuring pain, redness, itching, and burning — meaning no symptoms at all. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 39516454) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriasis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with moderate to severe plaque psoriasis for at least 6 months before the study starts.
- You have been taking secukinumab or ixekizumab (specific biologic medications) as directed for at least 6 months, but the treatment is not working as well as expected.
- Your psoriasis currently affects between 3% and just under 10% of your body surface area, and a doctor has rated its severity as mild-to-moderate on a standard scale (sPGA score of 2 or 3).
- A doctor has determined that you are suitable to continue on a biologic therapy (a type of specialist medication).
Who may not be able to join:
- You have a history of certain other forms of psoriasis, such as erythrodermic psoriasis, pustular psoriasis, psoriasis caused or worsened by medication, new guttate psoriasis, or psoriatic arthritis (a joint condition linked to psoriasis).
- You have an active skin condition other than plaque psoriasis that could make it difficult to assess your psoriasis properly.
- You have a history of cancer or a suspected cancer in the last 5 years, unless it was a successfully treated non-melanoma skin cancer or a very early-stage cervical condition.
- You have had major surgery in the 12 weeks before the study starts, or major surgery is planned during the trial period.
- You have previously been treated with risankizumab or any medication that works by blocking a protein called IL-23 (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Proportion of Participants Achieving Static Physician Global Assessment (sPGA) 0/1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.